STOCK TITAN

Journey Medical Corporation (DERM) Stock News, Oct 2024-Mar 2025

DERM NASDAQ

Journey Medical Corporation develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. The company is a commercial-stage dermatology pharmaceutical issuer with a portfolio of branded prescription drugs marketed in the United States.

Recurring news for DERM centers on quarterly and annual financial results, corporate updates, and commercialization progress across its dermatology portfolio. Company updates frequently discuss Emrosi™, a modified-release minocycline product approved for inflammatory lesions of rosacea in adults, including payer access, group purchasing organization contracts, prescription demand, product revenue, and clinical data presentations or publications for Emrosi/DFD-29.

Rhea-AI Summary

Journey Medical (NASDAQ: DERM) has announced the launch and first prescriptions of Emrosi™, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory lesions of rosacea in adults. The medication, which received FDA approval in November 2024, is now available through specialty pharmacy chains.

Emrosi is the lowest-dose oral minocycline available, featuring a unique 10 mg immediate release and 30 mg extended release formulation. Clinical trials demonstrated superior efficacy compared to Oracea® and placebo while maintaining a comparable safety profile. The most common adverse reaction reported was dyspepsia, occurring in ≥1% of subjects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.94%
Tags
none
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) has scheduled the release of its year end 2024 financial results on Wednesday, March 26, 2025, after U.S. financial markets close. The commercial-stage pharmaceutical company, which specializes in marketing FDA-approved prescription pharmaceutical products for dermatological conditions, will host a conference call and audio webcast at 4:30 p.m. ET on the same day.

Interested U.S. participants can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join the conference call. Registration is available at https://dpregister.com/sreg/10197674/feaf5b7354. A live audio webcast will be accessible on the company's website and remain available for approximately 30 days after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological prescription products, has announced its participation in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California.

President and CEO Claude Maraoui will lead a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference. Investors can access the fireside chat webcast on Journey Medical's website investor section for approximately 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
conferences
Rhea-AI Summary

Journey Medical (NASDAQ: DERM) announced the publication of Phase 3 clinical trial results for Emrosi™ (DFD-29) in JAMA Dermatology. The trials demonstrated superior efficacy of DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules) compared to both Oracea® and placebo in treating rosacea.

Key findings from the MVOR-1 and MVOR-2 trials showed:

  • DFD-29 achieved 65.0% and 60.1% IGA treatment success rates respectively
  • Significant reduction in inflammatory lesions compared to alternatives
  • Superior reduction in erythema versus placebo
  • No major safety issues reported

The FDA approved Emrosi™ in November 2024 for treating inflammatory lesions of rosacea in adults, with launch expected in early spring 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) announced its participation in the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida, from March 7-11, 2025. The company will showcase Emrosi™, their newly FDA-approved treatment for inflammatory lesions of rosacea in adults, approved in November 2024.

Emrosi™, featuring 40 mg Minocycline Hydrochloride Modified-Release Capsules (10 mg immediate release and 30 mg extended release), is positioned as the lowest-dose oral minocycline available. According to the company, it demonstrates superior clinical outcomes for rosacea compared to placebo and Oracea® while maintaining a comparable safety profile.

The AAD annual meeting, with over 350 exhibitors and nearly 20,000 attendees, including 10,000+ medical personnel, will provide Journey Medical an opportunity to present their dermatology product portfolio at booth 2181.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) has announced a conference call and webcast scheduled for February 5, 2025, at 4:30 p.m. ET to discuss the commercial launch plan for Emrosi™, their newly FDA-approved treatment for inflammatory lesions of rosacea in adults.

The medication, which contains 40 mg Minocycline Hydrochloride in extended-release capsules, was developed in collaboration with Dr. Reddy's Laboratories and received FDA approval in November 2024. The company is currently completing manufacturing of launch quantities for the U.S. market and preparing their dermatology-focused sales force for the product rollout.

The conference call will be accessible via phone (1-866-777-2509 domestic, 1-412-317-5413 international) and webcast through Journey Medical's website. The most common adverse reaction reported in clinical trials was dyspepsia, occurring in ≥1% of subjects treated with Emrosi compared to placebo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
conferences
Rhea-AI Summary

Journey Medical (DERM) reported Q3 2024 financial results with total revenues of $14.6 million, marking a 4% decrease from Q3 2023. The company received FDA approval for Emrosi™, a treatment for inflammatory lesions of rosacea in adults, with launch expected in late Q1 or early Q2 2025. Q3 2024 showed a net loss of $2.4 million ($0.12 per share), compared to net income of $16.8 million in Q3 2023. Gross margin improved to 63.9% from 57.9% year-over-year. The company ended the quarter with $22.5 million in cash and cash equivalents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) has received FDA approval for Emrosi™, a 40 mg minocycline hydrochloride extended-release capsule for treating inflammatory lesions of rosacea in adults. The approval is backed by successful Phase 3 clinical trials where Emrosi demonstrated superior efficacy compared to both Oracea® 40 mg capsules and placebo. The trials met all co-primary and secondary endpoints with no significant safety concerns. Journey Medical plans to launch Emrosi in the U.S. market through its dermatology-focused sales force, with initial supply expected late Q1 or early Q2 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.78%
Tags
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) presented data on DFD-29, a minocycline-based treatment for rosacea, at the 44th Fall Clinical Dermatology Conference. The study compared DFD-29 (40mg) with doxycycline (40mg) over 21 days, showing DFD-29 achieved higher dermal concentrations from Day 1. The company's New Drug Application is under FDA review with a PDUFA date of November 4, 2024. The randomized study demonstrated that DFD-29's modified-release formulation maintained consistent plasma levels while providing superior skin penetration compared to doxycycline, with both treatments showing good tolerability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
none
Rhea-AI Summary

Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved prescription drugs for dermatological conditions, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is set to take place on Wednesday, October 9, 2024, in New York City.

Members of Journey Medical's management team will be attending one-on-one meetings during the conference. This participation highlights the company's commitment to engaging with investors and industry professionals in the healthcare sector.

The conference provides an opportunity for Journey Medical to showcase its focus on selling and marketing dermatological treatments, potentially attracting investor interest and fostering business relationships within the pharmaceutical industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences

FAQ

What is the current stock price of Journey Medical (DERM)?

Journey Medical (DERM) last closed at $3.90.

What is the market cap of Journey Medical (DERM)?

The market cap of Journey Medical (DERM) is approximately $110.1M.